| 注册
首页|期刊导航|世界中医药|乳核散结片抗炎镇痛的药理实验研究

乳核散结片抗炎镇痛的药理实验研究

黄秋凌 郑明翠 宁娜

世界中医药2023,Vol.18Issue(22):3202-3206,5.
世界中医药2023,Vol.18Issue(22):3202-3206,5.DOI:10.3969/j.issn.1673-7202.2023.22.007

乳核散结片抗炎镇痛的药理实验研究

Pharmacological Study of Ruhe Sanjie Tablet for Anti-inflammation and Analgesia

黄秋凌 1郑明翠 2宁娜1

作者信息

  • 1. 广州白云山中一药业有限公司,广州,510530
  • 2. 广州白云山奇星药业有限公司,广州,510530
  • 折叠

摘要

Abstract

Objective:To investigate the anti-inflammatory and analgesic effects of Ruhe Sanjie Tablet.Methods:Cotton pellet-in-duced granuloma formation of Sprague Dawley(SD)rats and the increase in capillary permeability of mice induced by xylene were used to observe the anti-inflammatory effect of Ruhe Sanjie Tablet.The acetic acid writhing experiment in mice was established to observe the analgesic effect of the prescription.Results:The low-,medium-and high-dose Ruhe Sanjie Tablet inhibited the prolifera-tion of rat granulation tissue,and there were differences compared with the blank control group(all P<0.05).The inhibition rates of the three doses were 30.0%,47.4%and 53.6%,respectively,showing a dose-effect relationship.Ruhe Sanjie Tablet at low,medium and high doses reduced the capillary permeability of mice,and the optical density(OD)was lower than that in the blank control group(all P<0.001).The inhibition rates of capillary permeability were 47.6%,55.0%and 65.2%,respectively,with a dose-effect relationship.Ruhe Sanjie Tablet at each dose lowered the number of writhing induced by acetic acid in mice(P<0.001),and the analgesic inhibition rates at low,medium and high dose were 34.2%,42.0%and 51.5%,respectively,presenting a dose-effect relationship.Conclusion:Pharmacological studies of Ruhe Sanjie Tablet indicates that it has anti-inflammatory and analgesic effects.

关键词

乳核散结片/抗炎/镇痛/疗效/药理实验/毛细血管通透性/结缔组织增生/乳癖消

Key words

Ruhe Sanjie Tablet/Anti-inflammation/Analgesia/Curative effect/Pharmacological study/Capillary permeability/Connective tissue hyperplasia/Rupixiao

分类

医药卫生

引用本文复制引用

黄秋凌,郑明翠,宁娜..乳核散结片抗炎镇痛的药理实验研究[J].世界中医药,2023,18(22):3202-3206,5.

基金项目

广东省重点领域研发计划项目(2020B1111110004) (2020B1111110004)

世界中医药

OA北大核心CHSSCDCSTPCD

1673-7202

访问量0
|
下载量0
段落导航相关论文